Research Information System
Van Tıp Dergisi, vol.32, no.1, pp.3-6, 2025 (Peer-Reviewed Journal)
Abstract Introduction: One of the important heterocyclic compounds that exhibit versatile biological activity properties such as anti -inflammatory, antioxidant, and anti-proliferative/anticancer activities are benzimidazole-based compounds. In this study, a new benzimidazolium salt was synthesized. The cytotoxicity of this newly synthesized compound on HepG2 and A549 cell lines was investigated. Methods: In this study, a new benzimidazole salt was synthesized. Then, the cytotoxic effects of this compound 4 on the human liver cancer cell line (HepG2) and human lung cancer cell line (A549) were investigated by the MTT method. Result: According to the results obtained, it was concluded that compound 4, when applied to the human liver cancer cell line and the human lung cancer cell line under in vitro conditions, showed a significant cytotoxic effect on these cells. Cellular proliferation was measured for both lung A549 and liver HepG2 cells. Lung and liver cells exposed to various concentrations of compound 4 and cisplatin were observed at the 72-hour time point. Significant differences were detected in A549 cells treated with different concentrations of compound 4 and cisplatin (p=0.001<0.05). The doses that created the difference were found to be between 200 μM and 25 μM for compound 4 (p = 0.017) and between 200 μM and 50 μM concentrations (p = 0.001). There were also significant differences between doses for cisplatin (p=0.001<0.05). The concentrations that created the difference were found to be between 100 μM and 25 μM (p = 0.042), between 200 μM and 25 μM (p = 0.001), and between 200 μM and 50 μM (p = 0.049). As seen in Figure 1, cell viability in the high-dose compound 4 and cisplatin-treated groups (200 μM, 100 μM) is lower than the viability of cells in the low-dose compound 4 groups (50 μM, 25 μM). There is a difference between compound 4 and cisplatin (p<0.05). In terms of cell viability, the average of cisplatin was lower than compound 4. In the treatment of HepG2 cells with different doses of compound 4 and cisplatin, significant differences were detected between compound 4 and cisplatin (p=0.035<0.05). In terms of cell viability, the average of cisplatin was higher than that of compound 4. Discussion and Conclusion: Benzimidazole derivatives have various biological activities, including antitumor activity. Several investigations have exhibited the bioactivities of benzimidazole derivatives as possible therapies against cancer by focusing on certain molecules or employing non-gene-specific approaches. We tested this compound against two different human cancer cell lines including lung and liver. The results show that compound 4 had cytotoxic effects on both A549 and HepG2. Keywords: Cytotoxic activity; N-phenyl benzimidazole; HepG2, A549; cisplatin.